Quoin Pharmaceuticals said the U.S. FDA granted Fast Track designation to its QRX003 lotion (4%) for Netherton Syndrome, a regulatory status intended to speed development and potentially accelerate review. The company noted QRX003 previously received FDA Pediatric Rare Disease and Orphan Drug designations, and EMA Orphan Drug designation, which can provide incentives such as market exclusivity upon approval, tax credits and fee reductions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603110830PRIMZONEFULLFEED9669655) on March 11, 2026, and is solely responsible for the information contained therein.